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UNRELATED STEM CELL TRANSPLANTATION (SCT) FOR FANCONI ANE-
MIA(FA) USING CYCLOPHOSPHAMIDE(CY)  FLUDARABINE(FLU) 
THYMOGLOBULINE(THYMO): CONSECUTIVE ANALYSIS OF 20 PA-
TIENTS TREATED AT THE SAME INSTITUITION
Bonﬁm, C.M.S.; Bitencourt, M.A.; Setubal, D.C.; Funke, V.A.M.;
Ruiz, J.; Aduan, M.; Dourado, D.; de Medeiros, C.R.; Zanis-Neto, J.;
Pasquini, R. Bone Marrow Transplantation Service, Hospital de Clinicas
da UFPR, Curitiba, PR, Brazil.
Background: From 1983 until September 2004, 147 patients
received a SCT for FA in our BMT center and most of them were
in aplastic phase. In this study we selected 20 consecutive patients
who received an unrelated SCT for this disease using the same
preparative regimen. Patients and Methods: Period: 02/2000 to
09/2004; median age: 8 years (range, 4–14 years); sex: 13 females
and 7 males; median disease duration, 36 month (range, 7–67
months); previous transfusions: 1–65 UI(median, 12 UI); aplastic
phase: 20 patients; stem cell source: bone marrow (BM), 6 patients,
cord blood (CB), 14 patients; HLA disparities in 12 patients;
preparative regimen: CY 60mg/kg  FLU125 mg/m2  THY-
MO(rabbit) 4 mg/kg; GVHD prophylaxis: cyclosporine (Csa) 
MTX, 6 patients (BM) or Csa  steroids, 14 patients(CB).
All patients received prophylactic antibiotics according to com-
mon practice. Results: Eleven patients (55%) are alive and well
55–566 days after transplant (M:169d). Median time to reach
PMN 500/l was 23 days and that to reach platelets 20.000/l
was 25 days after transplantation. Seventeen patients were evalu-
able for engraftment (3 patients died before day 28), and 14
patients achieved complete hematologic recovery. Three pa-
tients had only neutrophil engraftment, and they all died early
after transplantation (on day 32, 34, and 58) due to infec-
tion complications. Nine patients died in the entire cohort be-
tween day 7 and 120 (median, 34 days), and in 8 patients
infection was the main cause of death. Acute GVHD grade II-IV
developed in 5 of 17 evaluable patients; chronic GVHD, in 1 of 10
evaluable patients. Mucositis grade III-IV occurred in 9 patients.
Due to delayed immune reconstitution, EBV lymphoproliferative
disease occurred in 3 patients, and in 1 of them it was the main
cause of death. Two patients treated with rituximab are alive and
well 6 and 10 months after EBV infection. There was no signiﬁcant
difference in survival for patients receiving BM or CB (67% vs
50%; P  .52). Patients receiving BM had a higher incidence of
mucositis grade III-IV (83%) compared with CB (29%). Acute
GVHD was the same in both groups and we did not observe
chronic GVHD in patients receiving BM. Conclusions: The use
of CY  FLU  THYMO as a preparative regimen in patients
with FA provided rapid and sustained engraftment for most pa-
tients. However, transplantation-related mortality is still very high,
and opportunistic infections occurring in the ﬁrst 100 days remain
the major causes of morbidity and mortality in this group of
patients.
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FACTORS INFLUENCING THE SUCCESS OF UNRELATED STEM CELL
DONOR (URD) SEARCH
Hong, S.L.W.1; Chitphakdithai, P.1; Dodson, K.L.1; Matlack, M.E.1;
Coppo, P.A.1; Weisdorf, D.J.2; Confer, D.L.1; Karanes, C.1 1. National
Marrow Donor Program, Minneapolis, MN; 2. Center for International
Blood & Marrow Transplant Research, Minneapolis, MN.
The NMDP retrospectively evaluated 2543 URD search pro-
cesses initiated between January 1, 2003 and June 30, 2003 in 3
groups of domestic transplant centers (TCs): 13 large research TCs
(RTCs), 25 growing TCs (GTCs), and 76 smaller TCs (STCs).
Each search was followed for 6 months. The number of patients
and donors at each stage, length of time between search stages,
search cancellations, level of HLA matching, the number of donors
requested at ﬁrst activation and donor availability were analyzed.
GTC had the shortest time from search to transplant (median, 83.5
days) versus STC (median, 85 days) or RTC (median, 93 days). In
addition, GTC searches more frequently resulted in transplants
(39%) versus STC (35%) or RTC (33%). Caucasian patients pro-
gressed to transplants nearly twice as frequently as others. Younger
patients ( 20 years), those with 75 potentially matched donors,
and those requested more than 4 donors at ﬁrst activation were
more frequently able to proceed to transplant. When the 978
potential donors were identiﬁed and requested for workup, 32.5%
were cancelled and did not proceed to transplant (11% for donor-
related reasons and 21.5% for recipient reasons). These data sug-
gest that search strategy and TC factors (ie, requesting more
donors, growing TC) lead to shorter and more successful searches.
Likelihood of transplant is less for non-Caucasian and non-His-
panic recipients. Efforts directed toward enhancing search efﬁ-
ciency may increase the chances of successful URD search and an
eventual transplant.
Percentages of Patients who Progressed from Search to Transplant
and Odds Ratio Estimates from Multivariate Logistic Regression
Factor
Percentage
Progressed
from
Search to
Transplant
Odds
Ratio 95% CI.
P-
Value
Favorable
Characteristic
Patient Race/
Ethnicity
Caucasian 39% 1.00 — —
Black/African
American 18% 0.44 (0.26, 0.74) 0.002 Caucasian
Hispanic 32% 0.57 (0.34, 0.96) 0.03
Other 21% 0.42 (0.27, 0.63) <0.0001
Patient Age
0-20 42% 1.00 — — 0–20
21-40 35% 0.65 (0.46, 0.91) 0.01
>40 21% 0.51 (0.37, 0.71) <0.0001
# 6 of 6 HLA
Matches
0-3 22% 0.49 (0.36, 0.65) <0.0001 >75
4-75 37% 1.00 — —
>75 46% 1.44 (1.11, 1.88) 0.006
# Donors at
First
Activation
1-4 32% 1.00 — — >4
>4 39% 1.35 (1.08, 1.68) 0.009
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1. Dana Farber Cancer Institute, Boston, MA; 2. Brigham and Wom-
en’s Hospital, Boston, MA.
The signiﬁcance of HLA disparity in URD NST has not been
elucidated. We performed a retrospective analysis of 115 patients
who underwent URD NST from July 2000-June 2004 for hema-
tologic cancers, mainly MDS, AML, CLL, and NHL. Eighty were
matched at HLA-A, B, C, DRB1, and DQB1. Thirty were single
antigen/allele mismatched at HLA-A (n  1), HLA-B (n  1),
HLA-C (n  19), or HLA-DQ (n  9). Five were double mis-
matched: HLA-AC (n  1), HLA-BC (n  3), and HLA-
DQC (n  1). All received nonmyeloablative conditioning with
intravenous busulfex 0.8 mg/kg/d and ﬂudarabine 30 mg/m2/d 4
days. GVHD prophylaxis consisted of a calcineurin inhibitor
(CI)  prednisone or CI  mini-methotrexate based therapy. The
2 cohorts were balanced for donor and recipient age, gender
disparity, and disease status. There was a trend toward more
steroid-based GVHD prophylaxis in the mismatched group. The
stem cell source was predominantly PBSC, although 8 of 35 (23%)
mismatched patients received marrow, compared with 3 of 80 (4%)
in the matched cohort (P  .01). Median donor chimerism was
high in both mismatched and matched groups (90% and 96% at 1
month post-NST, respectively; P  .46), and this was sustained at
3 months (97% vs 96%). Grade II-IV aGVHD was signiﬁcantly
increased in the mismatched group (23/34 [68%] vs 31/80 [39%];
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